|
Boston Scientific Announces
ACC.11 Schedule
Clinical presentations to include
12-month data on
PROMUS Element™
Platinum Chromium Stent
|
 |
PROMUS® Everolimus-
Eluting
Coronary
Stent |
|
March 29, 2011 -- Natick,
Massachusetts -- Boston Scientific Corporation (NYSE:
BSX) today announced its clinical trial news and events schedule
at the 60th Annual
Scientific Session of the American College of Cardiology/i2 Summit,
April 2-5, 2011 in New Orleans.
"Twelve-month results from the PLATINUM
Workhorse clinical trial will provide important data on our next-generation
PROMUS Element™ Everolimus-Eluting Platinum Chromium (PtCr) Stent
as compared to our market-leading PROMUS® Stent," said Keith D.
Dawkins, M.D., Senior Vice President and Chief Medical Officer
for Boston Scientific's Cardiology, Rhythm and Vascular (CRV) Group. "Additional
analysis from the PERSEUS trial will further demonstrate differences
in the PtCr platform compared to prior-generation stents." |
Schedule of Events (All times are CST, with events to be held at the Ernest N. Morial Convention Center.)
Sunday, April 3
- Comparison of PERSEUS/ATLAS trial data. Dean
Kereiakes, M.D., will present an analysis of case-matched data from 2,298
patients enrolled in the PERSEUS and TAXUS ATLAS clinical trials. The study
will compare nine-month angiographic and 12-month clinical outcomes of
the ION™ Paclitaxel-Eluting Platinum Chromium Coronary Stent System (TAXUS® Element™) to the TAXUS® Liberte® Paclitaxel-Eluting
Coronary Stent System. Both stents use the same drug and polymer but differ
in metal alloy composition, stent design and strut thickness. Results will
be presented from 10 to 11:15 a.m. during a poster session in Hall F. The
Company plans to issue a press release announcing trial results at this
time.
- Cost Effectiveness of ION Stent in Small Vessels. Mark
Turco, M.D., will present an analysis of the cost effectiveness of the
ION Stent (TAXUS
Element) versus the bare-metal Express® Stent in patients with small vessels.
Results will be presented from 10 to 11:15 a.m. during a poster session in
Hall F.
- PROMUS Stent in Small Vessels. Jennifer
Jones, M.D., will present 12-month results from the SPIRIT Small Vessel
trial evaluating the safety and
effectiveness of the 2.25 mm XIENCE V® (2.25 mm PROMUS®) Everolimus-Eluting
Coronary Stent System in treating coronary artery lesions in small vessels.
Results will be presented from 10 to 11:15 a.m. during a poster session in
Hall F.
Monday, April 4
- PLATINUM Workhorse 12-month outcomes. Gregg Stone, M.D., the Global Principal Investigator of the PLATINUM clinical program, will present 12-month results from the PLATINUM Workhorse trial. The randomized, controlled trial enrolled 1,530 patients at 132 sites worldwide and compares the PROMUS Element Everolimus-Eluting Platinum Chromium Coronary Stent System to the PROMUS Everolimus-Eluting Coronary Stent System. Results will be presented in a late-breaking trial session from 11:39 to 11:51 a.m. in the Main Arena. The Company plans to issue a press release announcing trial results at this time.
- HORIZONS AMI Diabetic analysis. Bernhard
Witzenbichler, M.D., will present results from an analysis of the HORIZONS
AMI trial on the safety and effectiveness of the TAXUS Express® Stent in
diabetic patients with acute myocardial infarction (AMI) undergoing primary
angioplasty. HORIZONS AMI is the largest randomized trial to compare the
use of drug-eluting stents to bare-metal stents for the treatment of heart
attack patients. Results will be presented during an oral contributions
session from 11:13 to 11:27 a.m. in Room 353.
- MADIT-CRT Changes in Outcomes after 12 months. Anne-Catherine Pouleur, M.D., will present results from the MADIT-CRT landmark clinical trial outlining the changes in left ventricle contractility and dyssynchrony after 12 months of resynchronization therapy. Results will be presented from 9:30 to 10:45 a.m. during a poster session in Hall F.
- MADIT-CRT Gender Relationship between QRS and Dyssynchrony. Dorit Knappe, M.D., will present results from the MADIT-CRT trial exploring gender relationships between QRS width and mechanical dyssynchrony. Results will be presented from 3:30 to 4:45 p.m. during a poster session in Hall F.
- Analyst Meeting. Boston Scientific will hold an analyst event providing an update on CRV Group initiatives involving coronary stent and structural heart technologies. The event is scheduled to begin at 6 p.m. and adjourn at approximately 7:15 p.m. following a brief question-and-answer session.
A live webcast of the event will be available to all interested parties via Boston Scientific's website at www.bostonscientific.com. Webcast registration is available on the Investor Relations section of the website. Interested parties are encouraged to register at least 15 minutes prior to the scheduled start time to ensure a timely connection. A webcast replay will be archived and available on the Investor Relations section of the Company's website approximately one hour following the completion of the event.
- Boston Scientific-Sponsored Symposium. The
Company has provided an educational grant to theheart.org to support a
CME-accredited symposium titled "Evolution in Stent Science: Understanding Tomorrow's Technology Today," chaired
by Ted Feldman, M.D. The event will take place at The Westin New Orleans
Canal Place from 7 to 9 p.m. It will feature presentations by leading interventional
cardiologists examining the latest trends in coronary stent innovation,
associated economics and their potential effect on future treatment options.
A reception will be held prior to the symposium, beginning at 6:30 p.m.
Boston Scientific will present its latest drug-eluting stent, cardiac rhythm management, peripheral intervention and imaging technologies at booth #4121 in the Exhibit Hall.
TAXUS, Express, Liberte, PROMUS, Element and ION are trademarks of Boston Scientific Corporation or its affiliates. XIENCE V is a trademark of the Abbott Laboratories group of companies. The PROMUS Stent is a private-labeled XIENCE V Stent manufactured by Abbott and distributed by Boston Scientific. The SPIRIT clinical program is sponsored by Abbott.
In the U.S., the ION Stent, PROMUS Element Stent and 2.25 mm PROMUS (XIENCE V) Stent are investigational devices, limited by applicable law to investigational use only and not available for sale. The safety and effectiveness of the TAXUS Express Stent has not been established in diabetic patients or patients presenting with AMI.
About Boston Scientific
Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: www.bostonscientific.com.
Cautionary Statement Regarding Forward-Looking Statements
This press
release contains forward-looking statements within the meaning of Section 27A
of the Securities Act of 1933 and Section 21E of the Securities Exchange Act
of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and
similar words. These forward-looking statements are based on our beliefs, assumptions
and estimates using information available to us at the time and are not intended
to be guarantees of future events or performance. These forward-looking statements
include, among other things, statements regarding new product launches and
launch cadence, regulatory approvals, clinical trials, product performance
and competitive offerings. If our underlying assumptions turn out to be incorrect,
or if certain risks or uncertainties materialize, actual results could vary
materially from the expectations and projections expressed or implied by our
forward-looking statements. These factors, in some cases, have affected and
in the future (together with other factors) could affect our ability to implement
our business strategy and may cause actual results to differ materially from
those contemplated by the statements expressed in this press release. As a
result, readers are cautioned not to place undue reliance on any of our forward-looking
statements.
Factors that may cause such differences include, among
other things: future economic, competitive, reimbursement and regulatory
conditions; new product introductions; demographic trends; intellectual property;
litigation; financial market conditions; and future business decisions made
by us and our competitors. All of these factors are difficult or impossible
to predict accurately and many of them are beyond our control. For a further
list and description of these and other important risks and uncertainties
that may affect our future operations, see Part I, Item 1A – Risk Factors in
our most recent Annual Report on Form 10-K filed with the Securities and
Exchange Commission, which we may update in Part II, Item 1A – Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file hereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document.
Source: Boston Scientific Corporation
|
